OPHLF - Bristol Myers announce new late-stage data for Opdivo/ Cabometyx combo in kidney cancer

Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (EXEL) disclosed new data for Opdivo/ Cabometyx combo in a pivotal Phase 3 trial for the first-line treatment of advanced renal cell carcinoma.The trial sponsored by Bristol Myers Squibb and Ono Pharmaceutical (OPHLF) and co-funded by Exelixis, Ipsen (IPSEF), and Takeda Pharmaceutical (TAK) evaluate the safety and efficacy of combination doublet compared to sunitinib for the indication.The primary endpoint is progression-free survival (“PFS”), while the secondary endpoints include overall survival (“OS”) and objective response rate (“ORR”).PFS: The combination doubled median PFS (17.0 months vs. 8.3 months, respectively; HR 0.52; 95% CI: 0.43 to 0.64) vs sunitinib.ORR: Nearly twice as many patients responded to the combination vs. sunitinib (54.8% vs. 28.4%).OS: The drug combination maintained the OS improvement, with a 34% reduction in the risk of death compared to sunitinib (HR: 0.66; 95% CI: 0.50 to 0.87).After a median follow-up of two years

For further details see:

Bristol Myers announce new late-stage data for Opdivo/ Cabometyx combo in kidney cancer